SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
HEPA

Hepion Pharmaceuticals, Inc. (OTC:HEPA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.12+$0.02 (+17.82%)
 
Market cap
$1.39M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 10, 2014
Market Cap$1.39M+80.3%
Revenue (ttm)$0
Net Income-$7.30M+20.4%
EPS-$0.27+98.0%
Shares Out11.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,803
Open$0.12
Previous Close$0.10
Day's Range$0.09 - $0.12
52-Week Range$0.03 - $0.22
Beta1.69
AnalystsHold
Price Target$70.00(+58723.53%)
Earnings DateMar 3, 2027
+18.81% (1D)
No price history available.

About HEPA

Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.

Address
55 Madison Avenue, Morristown, NJ, 07960, US
Market Cap
1 million
Employees
2
Industrial Classification
Biotechnology

Hepion Pharmaceuticals, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
3rd Percentile Overall Score
HEPA InsiderScore:29 / 99

Hepion Pharmaceuticals, Inc. scored higher than 3% of companies evaluated by InsiderBuying, and ranked 97th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Hepion Pharmaceuticals, Inc. bought $10.0K of stock across 1 purchase in the last 90 days, the largest of them $10.0K.

Stake Increase

None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$1.24M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From HEPA’s reported statements · Q3 2026 (trailing 12 months) · 3 of 5 pillars

Next catalysts

1 Day
+17.82%
5 Days
+15.53%
1 Month
-11.85%
6 Months
+35.23%
1 Year
+80.30%

$HEPA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in HEPA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by HEPA's directors and management

Net Shares Purchased by Insiders−20M−10M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

HEPA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New HEPA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to HEPA from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from HEPA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
60.65
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
12
Sells
0
Buy Value
$1.24M
Distinct Buyers
6

Insider Score Trend Over Time

+29.2 since Sep 17
0255075100Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 60.9Sep 30 — Insider Score 60.6Oct 1 — Insider Score 60.4Oct 2 — Insider Score 52.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Oct 6 — Insider Score 63.9Oct 7 — Insider Score 63.7Oct 8 — Insider Score 63.1Oct 9 — Insider Score 63.7Oct 10 — Insider Score 63.6Oct 11 — Insider Score 63.8Oct 12 — Insider Score 63.9Oct 13 — Insider Score 63.7Oct 17 — Insider Score 63.2Oct 18 — Insider Score 63.3Oct 19 — Insider Score 63.2Oct 20 — Insider Score 62.6Oct 21 — Insider Score 63.1Oct 22 — Insider Score 62.5Oct 23 — Insider Score 62.4Oct 24 — Insider Score 62.4Oct 25 — Insider Score 62.2Oct 26 — Insider Score 62.8Oct 27 — Insider Score 62.8Oct 28 — Insider Score 62.8Oct 29 — Insider Score 62.2Oct 30 — Insider Score 62.0Oct 31 — Insider Score 61.9Nov 1 — Insider Score 42.5Nov 2 — Insider Score 41.7Nov 3 — Insider Score 41.7Nov 4 — Insider Score 40.1Nov 5 — Insider Score 40.3Nov 6 — Insider Score 39.3Nov 7 — Insider Score 38.7Nov 8 — Insider Score 39.5Nov 9 — Insider Score 40.0Nov 10 — Insider Score 38.4Nov 11 — Insider Score 37.5Nov 12 — Insider Score 37.2Nov 13 — Insider Score 35.9Nov 14 — Insider Score 34.8Nov 15 — Insider Score 35.3Nov 16 — Insider Score 34.9Nov 17 — Insider Score 33.6Nov 21 — Insider Score 28.5Nov 22 — Insider Score 29.2Sep 17Oct 20Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.